Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin‐Piperaquine as Malaria Chemoprevention. Issue 6 (22nd July 2019)

• Record Type: Journal Article
• Authors: Whalen, Meghan E.; Kajubi, Richard; Chamankhah, Nona; Huang, Liusheng; Orukan, Francis; Wallender, Erika; Kamya, Moses R.; Dorsey, Grant; Jagannathan, Prasanna; Rosenthal, Philip J.; Mwebaza, Norah; Aweeka, Francesca T.
• Is Part Of: Clinical pharmacology & therapeutics. Volume 106:Issue 6(2019)
• Page Start: 1310
• Page End: 1318
• Publication Date: 2019-07-22
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1534
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Dihydroartemisinin (DHA)‐piperaquine is being evaluated as intermittent preventive therapy for malaria, but dosing has not been optimized for children. We assessed exposure to DHA and piperaquine in Ugandan children at two ages during infancy. Intensive sampling was performed in 32 children at 32 weeks of age, 31 children at 104 weeks, and 30 female adult controls. Compared with adults, DHA area under the concentration‐time curve (AUC0–8 hr ) was 52% higher at 32 weeks and comparable at 104 weeks. Compared with adults, piperaquine AUC0–21 d was 35% lower at 32 weeks and 53% lower at 104 weeks. Terminal piperaquine concentrations on days 7, 14, and 21 were lower in children compared with adults and lower at 104 compared with 32 weeks. Piperaquine exposure was lower in young children compared with adults, and lower at 104 compared with 32 weeks of age, suggesting a need for age‐based DHA‐piperaquine dose optimization for chemoprevention.